Literature DB >> 24728972

Soluble TNFα-receptor 1 as a predictor of coronary calcifications in patients after long-term cure of Cushing's syndrome.

María-José Barahona1, Eugenia Resmini, David Viladés, José-Manuel Fernández-Real, Wifredo Ricart, José-María Moreno-Navarrete, Guillem Pons-Lladó, Rubén Leta, Susan M Webb.   

Abstract

PURPOSE: Increased cardiovascular (CV) risk persists in Cushing's syndrome (CS), despite remission of hypercortisolism. The aim of this study was to evaluate prevalence of coronary artery disease in CS patients and its correlation with classical CV risk factors and inflammatory markers.
METHODS: Cardiac multidetector computed tomography (MDCT) was performed in 41 patients (7 men, 31 of pituitary origin, 29 cured, mean age: 48.6 ± 13 years), using 64-slice Toshiba Aquilion systems. Coronary atherosclerotic plaques were detected and coronary calcifications quantified by the Agatston score (AS). Clinical and biochemical parameters were correlated with the AS to identify possible surrogate markers of coronary disease. Normal values for clinical and biochemical parameters were obtained from a gender- and age-matched normal reference population (n = 82).
RESULTS: CS patients with calcifications (AS > 0) (N = 13, 32%) had higher levels of sTNF-R1, homocysteine, triglycerides, blood pressure and body mass index than patients without calcifications (AS = 0) and those of normal reference population. Both groups of CS patients (AS > 0 and AS = 0) had elevated trunk fat mass and IL-6 compared to reference values. Patients with AS > 0 had less adiponectin and higher insulin, HOMA and fibrinogen than those found in normal reference population. sTNF-R1 correlated positively with AS and remained significant after adjusting for confounding factors. The same result was observed when we considered only cured CS patients.
CONCLUSION: In our cohort of CS patients sTNF-R1 was a predictor of coronary calcifications. Since MDCT is an expensive technique not readily available in daily clinical practice, increased sTNF-R1 could be a marker of CV risk even in cured CS.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24728972     DOI: 10.1007/s11102-014-0566-9

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  28 in total

1.  ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography. A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance.

Authors:  Allen J Taylor; Manuel Cerqueira; John McB Hodgson; Daniel Mark; James Min; Patrick O'Gara; Geoffrey D Rubin; Christopher M Kramer; Daniel Berman; Alan Brown; Farooq A Chaudhry; Ricardo C Cury; Milind Y Desai; Andrew J Einstein; Antoinette S Gomes; Robert Harrington; Udo Hoffmann; Rahul Khare; John Lesser; Christopher McGann; Alan Rosenberg; Robert Schwartz; Marc Shelton; Gerald W Smetana; Sidney C Smith
Journal:  J Am Coll Cardiol       Date:  2010-11-23       Impact factor: 24.094

2.  Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men.

Authors:  Jan Frystyk; Christian Berne; Lars Berglund; Karin Jensevik; Allan Flyvbjerg; Björn Zethelius
Journal:  J Clin Endocrinol Metab       Date:  2006-11-21       Impact factor: 5.958

3.  Quantification of coronary artery calcium using ultrafast computed tomography.

Authors:  A S Agatston; W R Janowitz; F J Hildner; N R Zusmer; M Viamonte; R Detrano
Journal:  J Am Coll Cardiol       Date:  1990-03-15       Impact factor: 24.094

4.  Low plasma adiponectin concentration is an indicator of the metabolic syndrome.

Authors:  Merja Santaniemi; Y Antero Kesäniemi; Olavi Ukkola
Journal:  Eur J Endocrinol       Date:  2006-11       Impact factor: 6.664

5.  Long-term prognostic value of coronary calcification detected by electron-beam computed tomography in patients undergoing coronary angiography.

Authors:  P C Keelan; L F Bielak; K Ashai; L S Jamjoum; A E Denktas; J A Rumberger; P F Sheedy II; P A Peyser; R S Schwartz
Journal:  Circulation       Date:  2001-07-24       Impact factor: 29.690

6.  Coronary artery calcifications in children with end-stage renal disease.

Authors:  Mahmut Civilibal; Salim Caliskan; Ibrahim Adaletli; Huseyin Oflaz; Lale Sever; Cengiz Candan; Nur Canpolat; Ozgur Kasapcopur; Sebuh Kuruoglu; Nil Arisoy
Journal:  Pediatr Nephrol       Date:  2006-07-04       Impact factor: 3.714

7.  Coronary calcification in long-term type 1 diabetic patients -- a study with multi slice spiral computed tomography.

Authors:  C Thilo; E Standl; A Knez; M Reiser; G Steinbeck; R Haberl; O Schnell
Journal:  Exp Clin Endocrinol Diabetes       Date:  2004-11       Impact factor: 2.949

8.  Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance.

Authors:  J M Fernández-Real; M Broch; W Ricart; R Casamitjana; C Gutierrez; J Vendrell; C Richart
Journal:  Diabetes       Date:  1998-11       Impact factor: 9.461

9.  Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission.

Authors:  Antongiulio Faggiano; Rosario Pivonello; Stefano Spiezia; Maria Cristina De Martino; Mariagiovanna Filippella; Carolina Di Somma; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

10.  Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.

Authors:  Elisabet Svenungsson; Iva Gunnarsson; Guo-Zhong Fei; Ingrid E Lundberg; Lars Klareskog; Johan Frostegård
Journal:  Arthritis Rheum       Date:  2003-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.